Painreform Ltd. (NASDAQ: PRFX)

PainReform Ltd., also known as PRFX, is a clinical-stage specialty pharmaceutical company operating within the healthcare industry. The company specializes in the reformulation of established therapeutics, with a focus on providing an extended period of post-surgical pain relief without the need for repeated dose administration. This innovative approach reduces the potential need for the use of opiates, making it a significant player in the industry's efforts to combat the opioid epidemic.

PainReform's main business activities revolve around the development and commercialization of extended-release products for the treatment of post-operative pain. Its primary product candidate, PRF-110, is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure. This unique formulation provides localized and extended post-operative analgesia, reducing pain for up to 72 hours post-operatively. The product's physical characteristics, such as its high viscosity and clear appearance, contribute to its ease of use and well-tolerated nature.

The company's strategy involves incorporating generic drugs with its proprietary extended-release drug-delivery system to create extended-release drug products. This approach takes advantage of the 505(b)(2) regulatory pathway created by the FDA, expediting the development and commercialization process. PRF-110, for instance, pairs the company's patented, proprietary extended-release drug-delivery system with the well-characterized, safe, and approved local anesthetic ropivacaine, to treat post-surgical pain.

PainReform holds a significant competitive advantage in the market, with no other products offering the same level of pain relief and ease of use as PRF-110. Its unique formulation and delivery system make it an attractive option for both patients and healthcare providers. The company's position within the industry is further strengthened by its potential to significantly impact the opioid epidemic by reducing the need for opiates in post-operative pain management.

The company's customers primarily consist of healthcare providers and patients seeking alternative options for managing post-operative pain. PainReform's products are designed to be easy to use and provide extended relief from pain, making them an attractive option for this target market.

In terms of its product portfolio, PainReform has a strong pipeline of products in development, including extended-release products for the treatment of other indications. The company's extended-release drug-delivery system is a unique non-aqueous, viscous formulation that can be used for the delivery of many drugs that are currently difficult to administer for long-term, continuous dosing without an intravenous access.